Cash flow Attovia Therapeutics, Inc.

Stocks

ATTO

US04987L1026

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-08 EDT			5-day change	1st Jan Change
16.31 ^USD	-0.67%		-4.84%	-

09-20	Attovia Therapeutics, Inc.(NasdaqGM:ATTO) added to S&P TMI Index	CI
09-16	Attovia Therapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 10:00 AM

4fc.osZk2HwS9KlVX6OB15T3pymTqxeJhc_2X3VmP_0c4CM.2q0Mojtdx_MvMsKxluGc_mKm-VLG0529bBEVbK0v2GbxmRS1MFqm5iwb6g

Published financial data: ATTOVIA THERAPEUTICS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2024 (USD)	2025 (USD)
Revenues	-	1.35M
Total Revenues	-	1.35M
Cost of Goods Sold, Total	-	54.15M
Gross Profit	-	-52.8M
Selling General & Admin Expenses, Total	7.69M	14.36M
R&D Expenses	33.86M	-
Other Operating Expenses, Total	41.55M	14.36M
Operating Income	-41.55M	-67.16M
Interest And Investment Income	3.44M	6.63M
Net Interest Expenses	3.44M	6.63M
Other Non Operating Income (Expenses)	-1.68M	-95K
EBT, Excl. Unusual Items	-39.8M	-60.63M
EBT, Incl. Unusual Items	-39.8M	-60.63M
Earnings From Continuing Operations	-39.8M	-60.63M
Net Income to Company	-39.8M	-60.63M
Net Income - (IS)	-39.8M	-60.63M
Preferred Dividend and Other Adjustments	5.24M	-
Net Income to Common Incl Extra Items	-45.05M	-60.63M
Net Income to Common Excl. Extra Items	-45.05M	-60.63M
Per Share Items
Net EPS - Basic	-12.76	-15.35
Basic EPS - Continuing Operations	-12.76	-15.35
Basic Weighted Average Shares Outstanding	3.53M	3.95M
Net EPS - Diluted	-12.76	-15.35
Diluted EPS - Continuing Operations	-12.76	-15.35
Diluted Weighted Average Shares Outstanding	3.53M	3.95M
Normalized Basic EPS	-7.04	-9.59
Normalized Diluted EPS	-7.04	-9.59
Supplemental Items
EBITDA	-41.24M	-66.36M
EBITA	-41.55M	-67.16M
EBIT	-41.55M	-67.16M
Total Revenues (As Reported)	-	1.35M
Normalized Net Income	-24.88M	-37.89M
Supplemental Operating Expense Items
General and Administrative Expenses	7.69M	14.36M
Research And Development Expense From Footnotes	33.86M	33.86M
Stock-Based Comp., COGS (Total)	-	798K
Stock-Based Comp., R&D Exp. (Total)	468K	-
Stock-Based Comp., G&A Exp. (Total)	920K	1.59M
Total Stock-Based Compensation	1.39M	2.39M

Fiscal Period: December	2024 (USD)	2025 (USD)
Assets
Cash And Equivalents	30.63M	40.19M
Short Term Investments	38.69M	112M
Total Cash And Short Term Investments	69.32M	152M
Other Receivables	-	900K
Total Receivables	-	900K
Prepaid Expenses	3.16M	3.13M
Total Current Assets	72.48M	156M
Gross Property Plant And Equipment	3.53M	8.96M
Accumulated Depreciation	-295K	-1.1M
Net Property Plant And Equipment	3.23M	7.86M
Other Long-Term Assets, Total	1M	1.73M
Total Assets	76.72M	166M
Liabilities
Accounts Payable, Total	4.14M	3.55M
Accrued Expenses, Total	3.58M	5.08M
Current Portion of Leases	-	1.92M
Unearned Revenue Current, Total	-	450K
Total Current Liabilities	7.72M	11.01M
Long-Term Leases	-	3.34M
Other Non Current Liabilities	6.87M	755K
Total Liabilities	14.59M	15.1M
Preferred Stock Redeemable	109M	-
Preferred Stock Convertible	-	258M
Total Preferred Equity	109M	258M
Common Stock, Total	4K	4K
Additional Paid In Capital	3.49M	3.47M
Retained Earnings	-50.38M	-111M
Comprehensive Income and Other	67K	99K
Total Common Equity	-46.82M	-107M
Total Equity	62.13M	151M
Total Liabilities And Equity	76.72M	166M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	4.43M	4.43M
ECS Total Common Shares Outstanding	4.43M	4.43M
Book Value / Share	-10.58	-24.27
Tangible Book Value	-46.82M	-107M
Tangible Book Value Per Share	-10.58	-24.27
Total Debt	0	5.26M
Net Debt	-69.32M	-147M
Account Code - Inventory Valuation	3	3
Machinery, Total	1.96M	4.42M

Fiscal Period: December	2024 (USD)	2025 (USD)
Net Income	-39.8M	-60.63M
Depreciation & Amortization - CF	313K	804K
Depreciation & Amortization, Total	313K	804K
Amortization of Deferred Charges, Total - (CF)	-	393K
(Gain) Loss From Sale Of Asset	7K	7K
(Gain) Loss on Sale of Investments - (CF)	-681K	-2.66M
Stock-Based Compensation (CF)	1.39M	2.39M
Other Operating Activities, Total	2.2M	218K
Change In Accounts Payable	1.72M	180K
Change in Other Net Operating Assets	-181K	96K
Cash from Operations	-35.04M	-59.2M
Capital Expenditure	-1.77M	-2.31M
Investment in Marketable and Equity Securities, Total	-38.03M	-71.14M
Cash from Investing	-39.8M	-73.46M
Long-Term Debt Repaid, Total	-171K	-
Total Debt Repaid	-171K	-
Issuance of Common Stock	310K	194K
Issuance of Preferred Stock	82.63M	142M
Other Financing Activities, Total	-19K	-376K
Cash from Financing	82.75M	142M
Net Change in Cash	7.91M	9.36M
Supplemental Items
Levered Free Cash Flow	-	-40.21M
Unlevered Free Cash Flow	-	-40.21M
Change In Net Working Capital	-	-496K
Net Debt Issued / Repaid	-171K	-

Fiscal Period: December	2024 (USD)	2025 (USD)
Profitability
Return on Assets	-	-34.6
Return on Total Capital	-	-38.48
Return On Equity %	-	-56.95
Return on Common Equity	-	78.6
Margin Analysis
Gross Profit Margin %	-	-3.91K
SG&A Margin	-	1.06K
EBITDA Margin %	-	-4.92K
EBITA Margin %	-	-4.97K
EBIT Margin %	-	-4.97K
Income From Continuing Operations Margin %	-	-4.49K
Net Income Margin %	-	-4.49K
Net Avail. For Common Margin %	-	-4.49K
Normalized Net Income Margin	-	-2.81K
Levered Free Cash Flow Margin	-	-2.98K
Unlevered Free Cash Flow Margin	-	-2.98K
Asset Turnover
Asset Turnover	-	0.01
Fixed Assets Turnover	-	0.24
Short Term Liquidity
Current Ratio	9.39	14.2
Quick Ratio	8.98	13.92
Operating Cash Flow to Current Liabilities	-4.54	-5.38
Average Days Payable Outstanding	-	25.92
Long Term Solvency
Total Debt/Equity	-	3.49
Total Debt / Total Capital	-	3.37
LT Debt/Equity	-	2.22
Long-Term Debt / Total Capital	-	2.14
Total Liabilities / Total Assets	19.02	9.1
Total Debt / EBITDA	-	-0.08
Net Debt / EBITDA	1.68	2.22
Total Debt / (EBITDA - Capex)	-	-0.08
Net Debt / (EBITDA - Capex)	1.61	2.14
Growth Over Prior Year
Gross Profit, 1 Yr. Growth %	-	55.93
EBITDA, 1 Yr. Growth %	-	60.9
EBITA, 1 Yr. Growth %	-	61.62
EBIT, 1 Yr. Growth %	-	61.62
Earnings From Cont. Operations, 1 Yr. Growth %	-	52.33
Net Income, 1 Yr. Growth %	-	52.33
Normalized Net Income, 1 Yr. Growth %	-	52.33
Diluted EPS Before Extra, 1 Yr. Growth %	-	36.2
Net Property, Plant and Equip., 1 Yr. Growth %	-	143.2
Total Assets, 1 Yr. Growth %	-	116.24
Tangible Book Value, 1 Yr. Growth %	-	129.44
Common Equity, 1 Yr. Growth %	-	129.44
Cash From Operations, 1 Yr. Growth %	-	68.97
Capital Expenditures, 1 Yr. Growth %	-	30.53